IN SEARCH OF NOVEL PHARMACOLOGICAL THERAPIES FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.6210Keywords:
Chronic Obstructive Pulmonary Disease, Pulmonology, Pharmacological Treatment, Personalized Therapy, Biological TreatmentAbstract
Background: Chronic Obstructive Pulmonary Disease (COPD) remains a significant global health challenge. Its progressive nature and variability in symptoms—often resulting in exacerbations and hospitalizations—contribute to a lower quality of life, reduced physical activity, and impaired psychological well-being. Despite advances in treatment, tailored to symptom severity, disease progression continues to be a major challenge. Current pharmacological therapeutic strategies primarily involve bronchodilators and inhaled corticosteroids. However, there is a persistent need for more effective and targeted interventions.
Methods: A comprehensive literature review was conducted for English-language publications using databases such as PubMed. Meta-analyses, systematic literature reviews, randomised controlled trials, cohort studies, case-control studies and cross-sectional studies were included. Articles published after 2016 were reviewed; in the case of older articles, only those that made a significant new contribution to the field were taken into consideration. Methodological rigor and limitations of included studies were critically discussed.
Results: Several therapies have demonstrated clinically relevant effects in late-stage trials, leading to recent regulatory approvals in the United States: ensifentrine in 2024 as a dual PDE3/PDE4 inhibitor for maintenance treatment of COPD, dupilumab in 2024 as maintenance biologic therapy for COPD with an eosinophilic phenotype, and mepolizumab in 2025 as maintenance treatment for inadequately controlled eosinophilic COPD. Other investigational agents, including IL-33 pathway inhibitors such as itepekimab and tozorakimab, have produced mixed or emerging Phase III results.
Conclusions: This review examines recent advancements in COPD therapy, with an emphasis on ongoing research and emerging pharmacological candidates that hold promise for improving patient outcomes.
References
Miravitlles, M., & Ribera, A. (2017). Understanding the impact of symptoms on the burden of COPD. Respiratory research, 18(1), 67. https://doi.org/10.1186/s12931-017-0548-3
Chen, S., Kuhn, M., Prettner, K., Yu, F., Yang, T., Bärnighausen, T., Bloom, D. E., & Wang, C. (2023). The global economic burden of chronic obstructive pulmonary disease for 204 countries and territories in 2020-50: A health-augmented macroeconomic modelling study. The Lancet. Global health, 11(8), e1183–e1193. https://doi.org/10.1016/S2214-109X(23)00217-6
Al Wachami, N., Guennouni, M., Iderdar, Y., Boumendil, K., Arraji, M., Mourajid, Y., Bouchachi, F. Z., Barkaoui, M., Louerdi, M. L., Hilali, A., & Chahboune, M. (2024). Estimating the global prevalence of chronic obstructive pulmonary disease (COPD): A systematic review and meta-analysis. BMC public health, 24(1), 297. https://doi.org/10.1186/s12889-024-17686-9
Adeloye, D., Song, P., Zhu, Y., Campbell, H., Sheikh, A., Rudan, I., & NIHR RESPIRE Global Respiratory Health Unit (2022). Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: A systematic review and modelling analysis. The Lancet. Respiratory medicine, 10(5), 447–458. https://doi.org/10.1016/S2213-2600(21)00511-7
Li, H. Y., Gao, T. Y., Fang, W., Xian-Yu, C. Y., Deng, N. J., Zhang, C., & Niu, Y. M. (2023). Global, regional and national burden of chronic obstructive pulmonary disease over a 30-year period: Estimates from the 1990 to 2019 global burden of disease study. Respirology (Carlton, Vic.), 28(1), 29–36. https://doi.org/10.1111/resp.14349
Walters, E. H., Shukla, S. D., Mahmood, M. Q., & Ward, C. (2021). Fully integrating pathophysiological insights in COPD: An updated working disease model to broaden therapeutic vision. European respiratory review : an official journal of the European Respiratory Society, 30(160), 200364. https://doi.org/10.1183/16000617.0364-2020
Zhang, Y., Wang, L., Mutlu, G. M., & Cai, H. (2021). More to explore: Further definition of risk factors for COPD - differential gender difference, modest elevation in PM2.5, and e-Cigarette use. Frontiers in physiology, 12, 669152. https://doi.org/10.3389/fphys.2021.669152
Brandsma, C. A., Van den Berge, M., Hackett, T. L., Brusselle, G., & Timens, W. (2020). Recent advances in chronic obstructive pulmonary disease pathogenesis: From disease mechanisms to precision medicine. The Journal of pathology, 250(5), 624–635. https://doi.org/10.1002/path.5364
Venkatesan, P. (2024). GOLD COPD report: 2024 update. The Lancet. Respiratory medicine, 12(1), 15–16. https://doi.org/10.1016/S2213-2600(23)00461-7
Vogelmeier, C. F., Román-Rodríguez, M., Singh, D., Han, M. K., Rodríguez-Roisin, R., & Ferguson, G. T. (2020). Goals of COPD treatment: Focus on symptoms and exacerbations. Respiratory medicine, 166, 105938. https://doi.org/10.1016/j.rmed.2020.105938
Bourbeau, J., Bhutani, M., Hernandez, P., Aaron, S. D., Beauchesne, M. F., Kermelly, S. B., D'Urzo, A., Lal, A., Maltais, F., Marciniuk, J. D., Mulpuru, S., Penz, E., Sin, D. D., Van Dam, A., Wald, J., Walker, B. L., & Marciniuk, D. D. (2023). 2023 Canadian thoracic society guideline on pharmacotherapy in patients with stable COPD. Chest, 164(5), 1159–1183. https://doi.org/10.1016/j.chest.2023.08.014
Nici, L., Mammen, M. J., Charbek, E., Alexander, P. E., Au, D. H., Boyd, C. M., Criner, G. J., Donaldson, G. C., Dreher, M., Fan, V. S., Gershon, A. S., Han, M. K., Krishnan, J. A., Martinez, F. J., Meek, P. M., Morgan, M., Polkey, M. I., Puhan, M. A., Sadatsafavi, M., Sin, D. D., … Aaron, S. D. (2020). Pharmacologic management of chronic obstructive pulmonary disease. An Official American Thoracic Society Clinical Practice Guideline. American journal of respiratory and critical care medicine, 201(9), e56–e69. https://doi.org/10.1164/rccm.202003-0625ST
Dong, L. L., Liu, Z. Y., Chen, K. J., Li, Z. Y., Zhou, J. S., Shen, H. H., & Chen, Z. H. (2024). The persistent inflammation in COPD: Is autoimmunity the core mechanism?. European respiratory review : an official journal of the European Respiratory Society, 33(171), 230137. https://doi.org/10.1183/16000617.0137-2023
Schmidt, M., Cattani-Cavalieri, I., Nuñez, F. J., & Ostrom, R. S. (2020). Phosphodiesterase isoforms and cAMP compartments in the development of new therapies for obstructive pulmonary diseases. Current opinion in pharmacology, 51, 34–42. https://doi.org/10.1016/j.coph.2020.05.002
Nourian, Y. H., Salimian, J., Ahmadi, A., Salehi, Z., Karimi, M., Emamvirdizadeh, A., Azimzadeh Jamalkandi, S., & Ghanei, M. (2023). CAMP-PDE signaling in COPD: Review of cellular, molecular and clinical features. Biochemistry and biophysics reports, 34, 101438. https://doi.org/10.1016/j.bbrep.2023.101438
Zuo, H., Cattani-Cavalieri, I., Musheshe, N., Nikolaev, V. O., & Schmidt, M. (2019). Phosphodiesterases as therapeutic targets for respiratory diseases. Pharmacology & therapeutics, 197, 225–242. https://doi.org/10.1016/j.pharmthera.2019.02.002
Facchinetti, F., Civelli, M., Singh, D., Papi, A., Emirova, A., & Govoni, M. (2021). Tanimilast, a novel inhaled Pde4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease. Frontiers in pharmacology, 12, 740803. https://doi.org/10.3389/fphar.2021.740803
Rennard, S., Knobil, K., Rabe, K. F., Morris, A., Schachter, N., Locantore, N., Canonica, W. G., Zhu, Y., & Barnhart, F. (2008). The efficacy and safety of cilomilast in COPD. Drugs, 68(Supplement 2), 3–57. https://doi.org/10.2165/0003495-200868002-00002
Shen, L. F., Lv, X. D., Chen, W. Y., Yang, Q., Fang, Z. X., & Lu, W. F. (2018). Effect of roflumilast on chronic obstructive pulmonary disease: A systematic review and meta-analysis. Irish journal of medical science, 187(3), 731–738. https://doi.org/10.1007/s11845-018-1738-9
OHTUVAYRE (ensifentrine) inhalation suspension: Full prescribing information [Package insert]. (2024). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217389s000lbl.pdf
Rabe, K. F., Rennard, S., Martinez, F. J., Celli, B. R., Singh, D., Papi, A., Bafadhel, M., Heble, J., Radwan, A., Soler, X., Jacob Nara, J. A., Deniz, Y., & Rowe, P. J. (2023). Targeting type 2 inflammation and epithelial alarmins in chronic obstructive pulmonary disease: A biologics outlook. American journal of respiratory and critical care medicine, 208(4), 395–405. https://doi.org/10.1164/rccm.202303-0455CI
Fermont, J. M., Masconi, K. L., Jensen, M. T., Ferrari, R., Di Lorenzo, V. A. P., Marott, J. M., Schuetz, P., Watz, H., Waschki, B., Müllerova, H., Polkey, M. I., Wilkinson, I. B., & Wood, A. M. (2019). Biomarkers and clinical outcomes in COPD: A systematic review and meta-analysis. Thorax, 74(5), 439–446. https://doi.org/10.1136/thoraxjnl-2018-211855
Osei, E. T., Brandsma, C. A., Timens, W., Heijink, I. H., & Hackett, T. L. (2020). Current perspectives on the role of interleukin-1 signalling in the pathogenesis of asthma and COPD. The European respiratory journal, 55(2), 1900563. https://doi.org/10.1183/13993003.00563-2019
Calverley, P. M. A., Sethi, S., Dawson, M., Ward, C. K., Finch, D. K., Penney, M., Newbold, P., & van der Merwe, R. (2017). A randomised, placebo-controlled trial of anti-interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease. Respiratory research, 18(1), 153. https://doi.org/10.1186/s12931-017-0633-7
Celli, B. R., Anzueto, A., Singh, D., Hanania, N. A., Fabbri, L., Martinez, F. J., Soler, X., Djandji, M., Jacob-Nara, J. A., Rowe, P. J., Deniz, Y., & Radwan, A. (2025). The emerging role of Alarmin-Targeting biologics in the treatment of patients with COPD. Chest, 167(5), 1346–1355. https://doi.org/10.1016/j.chest.2024.09.049
Yousuf, A. J., Mohammed, S., Carr, L., Yavari Ramsheh, M., Micieli, C., Mistry, V., Haldar, K., Wright, A., Novotny, P., Parker, S., Glover, S., Finch, J., Quann, N., Brookes, C. L., Hobson, R., Ibrahim, W., Russell, R. J., John, C., Grimbaldeston, M. A., Choy, D. F., … Brightling, C. E. (2022). Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): A phase 2a, placebo-controlled trial. The Lancet. Respiratory medicine, 10(5), 469–477. https://doi.org/10.1016/S2213-2600(21)00556-7
Reid, F., Singh, D., Muna Albayaty, Moate, R., Jimenez, E., Muhammad Waqas Sadiq, Howe, D., Gavala, M., Killick, H., Williams, A., Krishnan, S., Godwood, A., Shukla, A., Hewitt, L., Lei, A., Kell, C., Pandya, H., Newcombe, P., White, N., & Scott, I. C. (2024). A randomized phase 1 study of the anti‐interleukin‐33 antibody tozorakimab in healthy adults and patients with chronic obstructive pulmonary disease. Clinical Pharmacology and Therapeutics/Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3147
Rabe, K. F., Celli, B. R., Wechsler, M. E., Abdulai, R. M., Luo, X., Boomsma, M. M., Staudinger, H., Horowitz, J. E., Baras, A., Ferreira, M. A., Ruddy, M. K., Nivens, M. C., Amin, N., Weinreich, D. M., Yancopoulos, G. D., & Goulaouic, H. (2021). Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: A genetic association study and randomised, double-blind, phase 2a trial. The Lancet. Respiratory medicine, 9(11), 1288–1298. https://doi.org/10.1016/S2213-2600(21)00167-3
Rabe, K. F., Martinez, F. J., Bhatt, S. P., Kawayama, T., Cosio, B. G., Mroz, R. M., Boomsma, M. M., Goulaouic, H., Nivens, M. C., Djandji, M., Soler, X., Liu, Y., Kosloski, M. P., Xu, C. R., Amin, N., Staudinger, H., Lederer, D. J., & Abdulai, R. M. (2024). AERIFY-1/2: Two phase 3, randomised, controlled trials of itepekimab in former smokers with moderate-to-severe COPD. ERJ open research, 10(5), 00718-2023. https://doi.org/10.1183/23120541.00718-2023
Singh, D., Brightling, C. E., Rabe, K. F., Han, M. K., Christenson, S. A., Drummond, M. B., Papi, A., Pavord, I. D., Molfino, N. A., Almqvist, G., Kotalik, A., Hellqvist, Å., Gołąbek, M., Sindhwani, N. S., Ponnarambil, S. S., & COURSE study investigators (2025). Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): A randomised, placebo-controlled, phase 2a trial. The Lancet. Respiratory medicine, 13(1), 47–58. https://doi.org/10.1016/S2213-2600(24)00324-2
Pavord, I. D., Chapman, K. R., Bafadhel, M., Sciurba, F. C., Bradford, E. S., Schweiker Harris, S., Mayer, B., Rubin, D. B., Yancey, S. W., & Paggiaro, P. (2021). Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO. International journal of chronic obstructive pulmonary disease, 16, 1755–1770. https://doi.org/10.2147/COPD.S294333
Criner, G. J., Celli, B. R., Brightling, C. E., Agusti, A., Papi, A., Singh, D., Sin, D. D., Vogelmeier, C. F., Sciurba, F. C., Bafadhel, M., Backer, V., Kato, M., Ramírez-Venegas, A., Wei, Y. F., Bjermer, L., Shih, V. H., Jison, M., O'Quinn, S., Makulova, N., Newbold, P., … TERRANOVA Study Investigators (2019). Benralizumab for the prevention of COPD exacerbations. The New England journal of medicine, 381(11), 1023–1034. https://doi.org/10.1056/NEJMoa1905248
Bhatt, S. P., Rabe, K. F., Hanania, N. A., Vogelmeier, C. F., Bafadhel, M., Christenson, S. A., Papi, A., Singh, D., Laws, E., Patel, N., Yancopoulos, G. D., Akinlade, B., Maloney, J., Lu, X., Bauer, D., Bansal, A., Abdulai, R. M., Robinson, L. B., & NOTUS Study Investigators (2024). Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation. The New England journal of medicine, 390(24), 2274–2283. https://doi.org/10.1056/NEJMoa2401304
DUPIXENT (dupilumab) injection: Full prescribing information [Package insert]. (2024). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761055s064lbl.pdf
Ghalibaf, M. H. E., Kianian, F., Beigoli, S., Behrouz, S., Marefati, N., Boskabady, M., & Boskabady, M. H. (2023). The effects of vitamin c on respiratory, allergic and immunological diseases: An experimental and clinical-based review. Inflammopharmacology, 31(2), 653–672. https://doi.org/10.1007/s10787-023-01169-1
Tao, X., & Ye, X. (2025). Relationships between vitamin c intake and COPD assessed by machine learning approaches from the NHANES (2017-2023). Frontiers in nutrition, 12, 1563692. https://doi.org/10.3389/fnut.2025.1563692 37 Lei, T., Lu, T., Yu, H., Su, X., Zhang, C., Zhu, L., Yang, K., & Liu, J. (2022). Efficacy of Vitamin C Supplementation on Chronic Obstructive Pulmonary Disease (COPD): A Systematic Review and Meta-Analysis. International journal of chronic obstructive pulmonary disease, 17, 2201–2216. https://doi.org/10.2147/COPD.S368645
Lokesh, K. S., Chaya, S. K., Jayaraj, B. S., Praveena, A. S., Krishna, M., Madhivanan, P., & Mahesh, P. A. (2021). Vitamin d deficiency is associated with chronic obstructive pulmonary disease and exacerbation of COPD. The clinical respiratory journal, 15(4), 389–399. https://doi.org/10.1111/crj.13310
Ghosh, A. J., Moll, M., Hayden, L. P., Bon, J., Regan, E., Hersh, C. P., & COPDGene Investigators (2020). Vitamin d deficiency is associated with respiratory symptoms and airway wall thickening in smokers with and without COPD: A prospective cohort study. BMC pulmonary medicine, 20(1), 123. https://doi.org/10.1186/s12890-020-1148-4
Williamson, A., Martineau, A. R., Jolliffe, D., Sheikh, A., Janssens, W., Sluyter, J., Rafiq, R., de Jongh, R., & Griffiths, C. J. (2024). Vitamin d for the management of chronic obstructive pulmonary disease. The Cochrane database of systematic reviews, 9(9), CD013284. https://doi.org/10.1002/14651858.CD013284.pub2
Wang, Y., Wang, J., Chen, L., Zhang, H., Yu, L., Chi, Y., Chen, M., & Cai, Y. (2022). Efficacy of vitamin d supplementation on COPD and asthma control: A systematic review and meta-analysis. Journal of global health, 12, 04100. https://doi.org/10.7189/jogh.12.04100
Zhu, M., Wang, T., Wang, C., & Ji, Y. (2016). The association between vitamin d and COPD risk, severity, and exacerbation: An updated systematic review and meta-analysis. International journal of chronic obstructive pulmonary disease, 11, 2597–2607. https://doi.org/10.2147/COPD.S101382
Wang, L., Cai, Y., Garssen, J., Henricks, P. A. J., Folkerts, G., & Braber, S. (2023). The bidirectional Gut-Lung axis in chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine, 207(9), 1145–1160. https://doi.org/10.1164/rccm.202206-1066TR
Li, N., Dai, Z., Wang, Z., Deng, Z., Zhang, J., Pu, J., Cao, W., Pan, T., Zhou, Y., Yang, Z., Li, J., Li, B., & Ran, P. (2021). Gut microbiota dysbiosis contributes to the development of chronic obstructive pulmonary disease. Respiratory research, 22(1), 274. https://doi.org/10.1186/s12931-021-01872-z
Bowerman, K. L., Rehman, S. F., Vaughan, A., Lachner, N., Budden, K. F., Kim, R. Y., Wood, D. L. A., Gellatly, S. L., Shukla, S. D., Wood, L. G., Yang, I. A., Wark, P. A., Hugenholtz, P., & Hansbro, P. M. (2020). Disease-associated gut microbiome and metabolome changes in patients with chronic obstructive pulmonary disease. Nature communications, 11(1), 5886. https://doi.org/10.1038/s41467-020-19701-0
Qu, L., Cheng, Q., Wang, Y., Mu, H., & Zhang, Y. (2022). COPD and Gut-Lung axis: How microbiota and host inflammasome influence COPD and related therapeutics. Frontiers in microbiology, 13, 868086. https://doi.org/10.3389/fmicb.2022.868086
Su, Z., Ma, C., Ru, X., Zhang, S., Wu, C., Huang, Y., Cen, H., Yin, Z., & Zhang, J. (2024). Effects of probiotic treatment on patients and animals with chronic obstructive pulmonary disease: A systematic review and meta-analysis of randomized control trials. Frontiers in cellular and infection microbiology, 14, 1411222. https://doi.org/10.3389/fcimb.2024.1411222
Gulea, C., Zakeri, R., Alderman, V., Morgan, A., Ross, J., & Quint, J. K. (2021). Beta-blocker therapy in patients with COPD: A systematic literature review and meta-analysis with multiple treatment comparison. Respiratory research, 22(1), 64. https://doi.org/10.1186/s12931-021-01661-8
Tejwani, V., Fawzy, A., Putcha, N., Castaldi, P. J., Cho, M. H., Pratte, K. A., Bhatt, S. P., Lynch, D. A., Humphries, S. M., Kinney, G. L., D'Alessio, F. R., Hansel, N. N., & COPDGene Investigators (2021). Emphysema progression and lung function decline among angiotensin converting enzyme inhibitors and Angiotensin-Receptor blockade users in the COPDGene cohort. Chest, 160(4), 1245–1254. https://doi.org/10.1016/j.chest.2021.05.007
Han, N., Qi, H., Yin, Y., Liu, Y., Jin, P., Hou, Y., & Jia, Z. (2024). The effectiveness of vasodilators on chronic obstructive pulmonary disease: A systematic review and meta-analysis. Medicine, 103(46), e39794. https://doi.org/10.1097/MD.0000000000039794
Pelaia, C., Vatrella, A., Gallelli, L., Lombardo, N., Sciacqua, A., Savino, R., & Pelaia, G. (2021). Role of p38 Mitogen-Activated protein kinase in asthma and COPD: Pathogenic aspects and potential targeted therapies. Drug design, development and therapy, 15, 1275–1284. https://doi.org/10.2147/DDDT.S300988
Strâmbu, I. R., Kobalava, Z. D., Magnusson, B. P., MacKinnon, A., & Parkin, J. M. (2019). Phase II study of Single/Repeated doses of acumapimod (BCT197) to treat acute exacerbations of COPD. COPD, 16(5-6), 344–353. https://doi.org/10.1080/15412555.2019.1682535
Watz, H., Barnacle, H., Hartley, B. F., & Chan, R. (2014). Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: A randomised, double-blind, placebo-controlled trial. The Lancet. Respiratory medicine, 2(1), 63–72. https://doi.org/10.1016/S2213-2600(13)70200-5
Fisk, M., Cheriyan, J., Mohan, D., Forman, J., Mäki-Petäjä, K. M., McEniery, C. M., Fuld, J., Rudd, J. H. F., Hopkinson, N. S., Lomas, D. A., Cockcroft, J. R., Tal-Singer, R., Polkey, M. I., & Wilkinson, I. B. (2018). The p38 mitogen activated protein kinase inhibitor losmapimod in chronic obstructive pulmonary disease patients with systemic inflammation, stratified by fibrinogen: A randomised double-blind placebo-controlled trial. PloS One, 13(3), e0194197. https://doi.org/10.1371/journal.pone.0194197
Charron, C. E., Russell, P., Ito, K., Lea, S., Kizawa, Y., Brindley, C., & Singh, D. (2017). RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-α and -γ selectivity, suppresses COPD inflammation. The European respiratory journal, 50(4), 1700188. https://doi.org/10.1183/13993003.00188-2017
Mall, M. A., Criner, G. J., Miravitlles, M., Rowe, S. M., Vogelmeier, C. F., Rowlands, D. J., Schoenberger, M., & Altman, P. (2023). Cystic fibrosis transmembrane conductance regulator in COPD: A role in respiratory epithelium and beyond. The European respiratory journal, 61(4), 2201307. https://doi.org/10.1183/13993003.01307-2022
Martinez, F. J., Criner, G. J., Gessner, C., Jandl, M., Scherbovsky, F., Shinkai, M., Siler, T. M., Vogelmeier, C. F., Voves, R., Wedzicha, J. A., Bartels, C., Bottoli, I., Byiers, S., Cardenas, P., Eckert, J. H., Gutzwiller, F. S., Knorr, B., Kothari, M., Parlikar, R., Tanase, A. M., … Franssen, F. M. E. (2023). Icenticaftor, a CFTR potentiator, in COPD: A multicenter, Parallel-Group, Double-Blind clinical trial. American journal of respiratory and critical care medicine, 208(4), 417–427. https://doi.org/10.1164/rccm.202303-0458OC
Rowe, S. M., Jones, I., Dransfield, M. T., Haque, N., Gleason, S., Hayes, K. A., Kulmatycki, K., Yates, D. P., Danahay, H., Gosling, M., Rowlands, D. J., & Grant, S. S. (2020). Efficacy and safety of the CFTR potentiator icenticaftor (QBW251) in COPD: Results from a phase 2 randomized trial. International journal of chronic obstructive pulmonary disease, 15, 2399–2409. https://doi.org/10.2147/COPD.S257474
Vijaykumar, K., Solomon, G. M., Guimbellot, J., Acosta, E. P., Bhambhavni, P. G., White, S., Kim, H., Raju, S. V., Rasmussen, L. W., Harris, N., Liu, B., Hathorne, H., Rowe, S. M., & Dransfield, M. T. (2025). Ivacaftor for chronic obstructive pulmonary disease: Results from a phase 2, randomized controlled trial. American journal of respiratory and critical care medicine, 211(5), 823–831. https://doi.org/10.1164/rccm.202407-1302OC
Sciurba, F. C., et al. (2025). Mepolizumab to prevent exacerbations of COPD with an eosinophilic phenotype. The New England Journal of Medicine, 392(17), 1710–1720. https://doi.org/10.1056/NEJMoa2413181
U.S. Food and Drug Administration. (2025). Nucala (mepolizumab) for injection, for subcutaneous use: Prescribing information (Revised May 2025). https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125526s007lbl.pdf
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Jakub Wąsik, Aleksandra Marek, Wiktoria Balińska, Jagoda Rogowska
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
